ESMO/LinkedIn
Mar 22, 2025, 05:51
New insights into prognostic markers for rare adrenal cancers – ESMO
ESMO – European Society for Medical Oncology posted on LinkedIn:
“Phaeochromocytomas and paragangliomas (PPGLs) and adrenocortical carcinoma (ACC) are Rare Cancers with heterogeneous outcomes, but only limited information is available on prognostic factors.
As presented at ESMO Rare Cancers25, ctDNA tumour fraction was detectable in 19% of metastatic PPGL and was associated with 24-month overall survival (OS) rates of 24% versus 85% when ctDNA was undetected.
In a second study, researchers developed a new scoring system for ACC based on tumour burden, cortisol levels, performance status and neutrophil-to-lymphocyte ratio, with high scores associated with shorter OS.
Commentary from Alfredo Berruti in the ESMO Daily Reporter.”
Read Further about ESMO Rare Cancers 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 22, 2025, 05:51
Mar 21, 2025, 18:26